{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:08:33Z","timestamp":1783796913434,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003074","name":"ANPCyT","doi-asserted-by":"crossref","award":["PICT 2012-1228"],"award-info":[{"award-number":["PICT 2012-1228"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002923","name":"CONICET","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005746","name":"Universidad Nacional del Litoral, Argentina","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005746","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.vaccine.2015.01.044","type":"journal-article","created":{"date-parts":[[2015,1,25]],"date-time":"2015-01-25T05:00:19Z","timestamp":1422162019000},"page":"1274-1283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Iv\u00e1n Alejandro","family":"Bontempi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Hern\u00e1n","family":"Vicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvina Raquel","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia Bel\u00e9n","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Angel","family":"Roggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ameloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Callewaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rosa","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n Sergio","family":"Marcipar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.01.044_bib0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0002-8703(94)90521-5","article-title":"Treatment of chronic Chagas\u2019 disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up","volume":"127","author":"Viotti","year":"1994","journal-title":"Am Heart J"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/IAI.72.1.46-53.2004","article-title":"Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice","volume":"72","author":"Dumonteil","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0285","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.vaccine.2008.12.056","article-title":"Identification of novel vaccine candidates for Chagas\u2019 disease by immunization with sequential fractions of a trypomastigote cDNA expression library","volume":"27","author":"Tekiel","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0290","doi-asserted-by":"crossref","first-page":"e59434","DOI":"10.1371\/journal.pone.0059434","article-title":"TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice","volume":"8","author":"Gupta","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0295","doi-asserted-by":"crossref","first-page":"7356","DOI":"10.1128\/IAI.73.11.7356-7365.2005","article-title":"Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection","volume":"73","author":"Miyahira","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0300","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/erv.12.85","article-title":"Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects","volume":"11","author":"Dumonteil","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0305","doi-asserted-by":"crossref","first-page":"e25914","DOI":"10.1371\/journal.pone.0025914","article-title":"Genomic analyses, gene expression and antigenic profile of the trans-sialidase superfamily of Trypanosoma cruzi reveal an undetected level of complexity","volume":"6","author":"Freitas","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0310","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/B978-0-12-385863-4.00006-X","article-title":"Vaccine development against Trypanosoma cruzi and Chagas disease","volume":"75","author":"V\u00e1zquez-Chagoy\u00e1n","year":"2011","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0315","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.4049\/jimmunol.179.10.6889","article-title":"Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming","volume":"179","author":"Hoft","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0320","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/IAI.00278-09","article-title":"Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges","volume":"78","author":"Giddings","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0325","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V93.6.2025.406k19_2025_2032","article-title":"Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood","volume":"93","author":"Buscaglia","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0330","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/glycob\/cwh123","article-title":"Trypanosome trans-sialidase targets TrkA tyrosine kinase receptor and induces receptor internalization and activation","volume":"14","author":"Woronowicz","year":"2004","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0335","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.4049\/jimmunol.174.8.4545","article-title":"A sexual dimorphism in intrathymic sialylation survey is revealed by the trans-sialidase from Trypanosoma cruzi","volume":"174","author":"Mucci","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0340","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1286-4579(00)00333-6","article-title":"Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment","volume":"2","author":"Marcondes","year":"2000","journal-title":"Microbes Infect Inst Pasteur"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0345","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.vaccine.2008.02.060","article-title":"Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate","volume":"26","author":"Fontanella","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0350","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.vaccine.2009.05.032","article-title":"ISCOMs and ISCOMATRIX","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0355","first-page":"779","article-title":"Novel adjuvants and delivery vehicles for vaccines development: a road ahead","volume":"138","author":"Mohan","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0360","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14760584.6.5.761","article-title":"ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines","volume":"6","author":"Drane","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0365","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/prep.2000.1334","article-title":"Cloning of Trypanosoma cruzi trans-sialidase and expression in Pichia pastoris","volume":"20","author":"Laroy","year":"2000","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0370","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0375","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/CDLI.5.6.799-803.1998","article-title":"Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G","volume":"5","author":"Narita","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0380","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2249.2002.01874.x","article-title":"Differential susceptibility to acute Trypanosoma cruzi infection in BALB\/c and C57BL\/6 mice is not associated with a distinct parasite load but cytokine abnormalities","volume":"128","author":"Roggero","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0385","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2249.2009.03946.x","article-title":"Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation","volume":"157","author":"P\u00e9rez","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0390","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0166-6851(03)00093-8","article-title":"Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR","volume":"129","author":"Cummings","year":"2003","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0395","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0400","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1099\/jmm.0.040857-0","article-title":"ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases","volume":"61","author":"Morelli","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0405","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1128\/IAI.59.9.2909-2914.1991","article-title":"Immunization with Trypanosoma cruzi epimastigote antigens incorporated into iscoms protects against lethal challenge in mice","volume":"59","author":"Araujo","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0410","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-3024.1996.d01-40.x","article-title":"The flagellar fraction of Trypanosoma cruzi depleted of an immunosuppressive antigen enhances protection to infection and elicits spontaneous T cell responses","volume":"18","author":"Hansen","year":"1996","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0415","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0420","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/icb.2011.71","article-title":"ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway","volume":"90","author":"Wilson","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0425","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.4049\/jimmunol.1302011","article-title":"Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant","volume":"192","author":"Wilson","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0430","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00281-012-0351-7","article-title":"Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease","volume":"34","author":"Machado","year":"2012","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0435","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/IAI.64.6.1961-1967.1996","article-title":"Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes","volume":"64","author":"Aliberti","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0440","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1128\/IAI.68.1.197-204.2000","article-title":"Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi","volume":"68","author":"Hoft","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0445","doi-asserted-by":"crossref","first-page":"e1598","DOI":"10.1371\/journal.pntd.0001598","article-title":"IFN-\u03b3 plays a unique role in protection against low virulent Trypanosoma cruzi strain","volume":"6","author":"Rodrigues","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0450","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1084\/jem.20062175","article-title":"Conventional T-bet(+)Foxp3(\u2212) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection","volume":"204","author":"Jankovic","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0455","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1086\/596061","article-title":"Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy","volume":"199","author":"Costa","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0460","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ilar.46.3.280","article-title":"Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants","volume":"46","author":"Stills","year":"2005","journal-title":"ILAR J Natl Res Counc Inst Lab Anim Resour"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0465","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.micinf.2013.02.003","article-title":"Trans-sialidase from Trypanosoma cruzi enhances the adhesion properties and fibronectin-driven migration of thymocytes","volume":"15","author":"Nardy","year":"2013","journal-title":"Microbes Infect Inst Pasteur"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0470","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1017\/S0031182006001752","article-title":"Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections","volume":"134","author":"Risso","year":"2007","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0475","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1084\/jem.181.5.1693","article-title":"Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas\u2019 disease","volume":"181","author":"Chuenkova","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0480","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1016\/j.vaccine.2013.07.034","article-title":"Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX\u2122 adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques","volume":"31","author":"DiStefano","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0485","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.vaccine.2003.09.014","article-title":"ISCOM based vaccines for cancer immunotherapy","volume":"22","author":"Lenarczyk","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0490","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.coi.2009.07.006","article-title":"T cells in Trypanosoma cruzi infection","volume":"21","author":"Padilla","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0495","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0165-2478(00)00205-4","article-title":"CD4 Th1 but not Th2 clones efficiently activate macrophages to eliminate Trypanosoma cruzi through a nitric oxide dependent mechanism","volume":"73","author":"Rodrigues","year":"2000","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0500","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/IAI.69.9.5477-5486.2001","article-title":"DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene","volume":"69","author":"Fujimura","year":"2001","journal-title":"Infect Immun"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.01.044_bib0505","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1590\/S0074-02762009000900037","article-title":"Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice","volume":"104","author":"Rodrigues","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0510","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2217\/fmb.11.122","article-title":"The role of Toll-like receptors and adaptive immunity in the development of protective or pathological immune response triggered by the Trypanosoma cruzi protozoan","volume":"6","author":"Pellegrini","year":"2011","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0515","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4049\/jimmunol.1200061","article-title":"IFN-\u03b3 from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection","volume":"190","author":"Green","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0520","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1016\/j.vaccine.2012.10.018","article-title":"Delivery of antigenic candidates by a DNA\/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi","volume":"30","author":"Gupta","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0525","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4269\/ajtmh.1997.56.485","article-title":"Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis","volume":"56","author":"Higuchi","year":"1997","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0530","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1590\/S0074-02762011000100014","article-title":"Trypanosoma cruzi: parasite persistence in tissues in chronic chagasic Brazilian patients","volume":"106","author":"Marcon","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0535","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.vaccine.2008.02.011","article-title":"Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model","volume":"26","author":"Cazorla","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.044_bib0540","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1016\/j.vaccine.2014.04.026","article-title":"A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease","volume":"32","author":"Serna","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15000882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15000882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T09:44:46Z","timestamp":1598694286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0264410X15000882"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}